icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
" In view of :
- the efficacy and safety data versus placebo,
- the absence of direct comparative data versus other anti-ANF agents, particularly infliximab,
the Transparency Committee considers that SIMPONI (golimumab) does not provide any improvement in actual benefit (IAB V, non-existent) in the treatment of moderately to severely active UC which is resistant to conventional therapies."
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
QHF4h5yrxkzJ3N7n